Latest news

• Shire claims EU approval for haemophilia A drug Adynovi

  The European Commission has approved Shire’s haemophilia A therapy Adynovi, a new long-acting version of its long-established Advate product.

• Shire wins CHMP backing for Adynovi

  The injectable is a new form of Advate - a haemophilia A treatment Shire acquired from Baxalta in a $32bn takeover - and offers twice-weekly prophylactic use as well as on-demand

• Sobi looks to real-world trial to push Elocta take-up

  to wrest market share from established haemophilia A therapies such as Shire/Baxalta's Advate (octocog alfa).

• Baxalta agrees to $32bn Shire takeover

  The merger will couple Baxalta's haemophilia franchise - including its big selling Advate product for haemophilia A and long-acting follow-up BAX-855 which is nearing the market- with Shire

• First von Willebrand disease therapy heads new FDA approvals

  Last month it secured FDA approval for long-acting haemophilia A therapy Adynovate (formerly BAX 855), a follow-up to its big-selling Advate brand.